ADIAL PHARMACEUTICALS, INC. short interest in 2025
In 2025, ADIAL PHARMACEUTICALS, INC.'s disclosed short interest ran from 1.51% of shares outstanding on 14 Feb 2025 to 1.61% on 31 Dec 2025, a change of +0.10 percentage points. The year's high was 11.82% on 30 Jun 2025 and its low 1.51% on 14 Feb 2025, averaging 4.96% across 19 twice-monthly settlement dates. FINRA's days-to-cover figure peaked at 6.23 days on 14 Mar 2025. Full history: ADIAL PHARMACEUTICALS, INC..
Cite this page
By year: 2019 · 2020 · 2021 · 2022 · 2023 · 2024 · 2025 · 2026
2025 in figures
- Start of year
- 1.51% (14 Feb 2025)
- End of year
- 1.61% (31 Dec 2025)
- Change
- +0.10 pp
- High
- 11.82% (30 Jun 2025)
- Low
- 1.51% (14 Feb 2025)
- Average
- 4.96%
- Highest days to cover
- 6.23 (14 Mar 2025)
- SEC filings marked
- 8
Every report in 2025
| Settlement | Short interest | Days to cover | Filings since previous |
|---|---|---|---|
| 14 Feb 2025 | 1.51% | 1.19 | |
| 28 Feb 2025 | 10.42% | 1.00 | |
| 14 Mar 2025 | 8.36% | 6.23 | 10-K filed, results (8-K) |
| 31 Mar 2025 | 6.35% | 5.55 | |
| 15 Apr 2025 | 3.30% | 3.98 | |
| 30 Apr 2025 | 2.13% | 5.02 | |
| 15 May 2025 | 4.59% | 1.00 | 10-Q filed, results (8-K) |
| 13 Jun 2025 | 6.20% | 1.00 | |
| 30 Jun 2025 | 11.82% | 1.00 | |
| 15 Aug 2025 | 8.43% | 1.71 | 10-Q filed, results (8-K) |
| 29 Aug 2025 | 6.55% | 2.71 | |
| 15 Sep 2025 | 5.63% | 2.16 | |
| 30 Sep 2025 | 5.09% | 1.52 | |
| 15 Oct 2025 | 2.05% | 1.00 | |
| 31 Oct 2025 | 4.21% | 1.67 | |
| 14 Nov 2025 | 1.75% | 1.49 | 10-Q filed, results (8-K) |
| 28 Nov 2025 | 2.47% | 1.18 | |
| 15 Dec 2025 | 1.70% | 1.69 | |
| 31 Dec 2025 | 1.61% | 1.03 |
See also: ADIAL PHARMACEUTICALS, INC.'s full history · most shorted US stocks of 2025 · today's US league.
About this data
US short interest data: FINRA (finra.org), shown as reported shares short divided by SEC-reported shares outstanding for each settlement date. FINRA® is a registered trademark of the Financial Industry Regulatory Authority, Inc. This site is not affiliated with or endorsed by FINRA or the SEC; displayed for personal reference, bulk redistribution is not permitted (see terms). Nothing here is investment advice. Method: methodology.